Clinical Trial

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms

Study acronym: CAR19BCMA
Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 22, 2025 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single arm study to evaluate the safety and efficacy of CAR19BCMA CAR-T cells in the treatment of relapsed/refractory CD19/BCMA positive plasma cell neoplasms.
Trial Details
NCT Number NCT07077330
Lead Sponsor Chinese PLA General Hospital
Conditions Relapsed or Refractory Plasma Cell Neoplasms
Enrollment 20 participants
Start Date 2025-08-01
Primary Completion 2026-08-01 (estimated)
Study Completion 2027-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-22